Sign up Australia
Proactive Investors - Run By Investors For Investors

Creso Pharma targets Australia’s nascent market for medical cannabis

The move follows the legalisation of medical cannabis in Australia.
Creso Pharma targets Australia’s nascent market for medical cannabis
Creso Pharma targets Australia’s nascent market for medical cannabis

Creso Pharma (ASX:CPH) has signed its first letter of intent in Australia for the import and sale of medical cannabis products in the Australian market.

The move follows the legalisation of medical cannabis by the Federal Government in Australia last year and a supportive statement by the prime minister to initiate medical cannabis imports alongside building the local medical cannabis industry.

Creso has partnered with Western Australia-based pharmaceutical group, Health House International, for importing and selling medical cannabis products.

Coincidentally, fellow medical cannabis company Auscann Group Holdings (ASX:AC8) debuts on the ASX today.

Creso recently opened an office in Sydney, giving the company a presence on Australia’s east coast, adding to its existing office in Perth.

Health House International will initially conduct a trial import of cannabis oil products from Canadian-based third-parties introduced by Creso.

If the trial is successful, the parties have agreed to enter into an agreement for an initial two-year term, subject to Health House importing the agreed minimum quantities.

Creso will act as the exclusive facilitator for the import of the products into Australia and earn a facilitation fee on each Health House import.

Once imported, Health House International will look to distribute the products to Australian patients that can buy medical cannabis under the new Australian law.

Creso is a pioneer in cannabidiol (CBD) innovation and develops cannabis and hemp-derived therapeutic-grade CBD nutraceuticals and medical cannabis products for human and animal health.

The company started trading on the ASX in October 2016 following a successful A$5 million capital raising that was significantly oversubscribed.

Creso is well funded with a cash balance of about $3 million as at 31 December 2016.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full . profile View Profile

Proactive Investors Australia Timeline

Related Articles

April 16 2018
Global pharmaceutical R&D is forecast to reach $182bn by 2022 having grown at near 4% annually since 2006
Milan Patel, dotdigital’s chief executive officer said: "This year reflects substantial progress against the company's strategic aims in accelerating our platform capabilities into the omnichannel space, continuing to innovate our product, growing geographically and deepening our relationships with our strategic partners”
July 11 2018
From an almost standing start in 2016, the group is scheduled to run Bricklive banded shows at 60 venues this year

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use